This disclosure provides compositions and methods for T-
cell mediated depletion of B cells. The compositions and methods may be used, for example, for the treatment of autoimmune disorders, immune-mediated
inflammation disorders and other B-
cell mediated immune disorders. In embodiments, the depletion is effected by methods comprising administering to an individual a
T cell engaging
protein ("TEP"), wherein the TEP comprises: (i)
a peptide-
major histocompatibility complex ("pMHC") comprising
a peptide epitope, a β2-microglobulin ("β2M") polypeptide, and an
MHC class I heavy chain polypeptide; (ii) an immunoglobulin ("Ig") Fc polypeptide; (iii) at least one B-
cell targeting component; and (iv) optionally one or more activating immunomodulatory polypeptides, wherein each of the at least one B-
cell targeting components of the TEP binds to a
B cell binding partner on a
B cell, a plasmablast, and / or a
plasma cell.